Deep Sequencing Instrumentation Upgrade - Illumina HiSeq2500

深度测序仪器升级 - Illumina HiSeq2500

• 批准号: 8640603
• 负责人: Charis Eng
• 金额: $ 60万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-06-15 至 2015-06-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8640603
• 关键词: Biological Markers; Chemistry; Clinic; Clinical; Commit; DNA; DNA Fingerprinting; Development; Ensure; Epigenetic Process; Functional RNA; Funding; Gene Expression Profile; Gene Expression Profiling; Genome; Genomics; Health system; Human; Institute of Medicine (U.S.); Institution; Libraries; Lifting; Maintenance; Marketing; Massive Parallel Sequencing; Medicine; Metagenomics; Ohio; Output; Patients; Reading; Regulation; Research; Research Infrastructure; Research Institute; Research Personnel; Resources; Running; Sampling; Seeds; Services; Small RNA; System; Technology; Time; Transcript; Translational Research; United States National Institutes of Health; base; cost effective; deep sequencing; disease-causing mutation; exome sequencing; flexibility; genetic regulatory protein; genome sequencing; genome-wide; human disease; instrument; instrumentation; metagenome; methylome; next generation; novel; operation; transcriptome sequencing; translational study

DESCRIPTION (provided by applicant): The purpose of this application is to leverage our Illumina Genome Analyzer IIx (GAIIx) next generation sequencer asset to upgrade and better serve the deep sequencing needs of investigators within the Lerner Research Institute and the research enterprise of the Cleveland Clinic Health System by requesting funds to purchase the higher throughput, flexible, state-of-the-art, Illumina HiSeq2500 instrument system. The HiSeq2500 instrument is the latest in the Illumina suite of massively parallel sequencing instruments developed as a direct consequence of the NIH initiative for the $1,000 genome project. It has a higher sequence read output, a rapid-run mode for greater flexibility enabling a wider range of genome-scale applications while being more cost effective to run than the GAIIx. The HiSeq2500 represents the most versatile, in terms of applications capabilities, of the Illumina instruments and technologies to come to the market. The underlying technology can be summarized as massively parallel sequencing using bead-based flowcells with single base synthesis TruSeq v3 chemistry (maximum output 600 Gb of sequence in a typical 10 day high throughput run). As detailed in the application, the instrument and technology will support our projects that primarily include biomarker discovery, transcriptome, methylome, metagenome and clinical/translational studies that represent the unique strengths of our institution. The projects will take advantage of the HiSeq2500 advances of scale, versatility and higher sample multiplexing capability. Higher numbers of output reads per flowcell than the GAIIx leads to higher library multiplexing capability for RNA-seq resulting in less expense per sample, better dynamic range than microarray profiling, the ability to reliably detect low- abundance transcripts and to discover novel transcripts for whole transcriptome, small or non-coding RNA discovery and gene expression profiling. The HiSeq2500 takes less time to complete genome- wide profiles of DNA-protein regulatory interactions, epigenetic regulation, whole genome sequencing, exome sequencing, re-sequencing of large genomic regions in translational research with patient DNA to uncover human disease causing mutations and translational metagenomic studies of human gut flora. The HiSeq2500 is essential to lift the current NIH-funded projects to the next level and to seed new endeavors in northeast Ohio. Cleveland Clinic has already committed substantial resources to the development of translational genomics and genomic medicine by founding the LRI-Genomics Core within the Genomic Medicine Institute and by supporting its operation within the larger Research Core Services infrastructure to ensure its operation and maintenance for the long-term.

DESCRIPTION (provided by applicant): The purpose of this application is to leverage our Illumina Genome Analyzer IIx (GAIIx) next generation sequencer asset to upgrade and better serve the deep sequencing needs of investigators within the Lerner Research Institute and the research enterprise of the Cleveland Clinic Health System by requesting funds to purchase the higher throughput, flexible, state-of-the-art, Illumina HiSeq2500 instrument system. HISEQ2500仪器是Illumina套件中最新的一系列大规模平行测序仪器，这是NIH计划的直接结果，该计划是1,000美元的基因组项目。它具有较高的序列读取输出，这是一种快速运行模式，可实现更大的灵活性，可实现更广泛的基因组规模应用，同时比Gaiix更具成本效益。 HISEQ2500代表了Illumina仪器和技术来推向市场的功能，这是最通用的功能。基础技术可以总结为具有单基合成Truseq V3化学（最大输出600 GB序列的最大输出序列，在典型的10天高吞吐量运行中最大输出600 GB）的基于珠的流动周期（最大输出600 GB）。如应用程序中所述，该工具和技术将支持我们的项目，其中主要包括生物标志物发现，转录组，甲基组，元基因组和临床/翻译研究，这些研究代表了我们机构的独特优势。这些项目将利用HISEQ2500规模，多功能性和较高样本多路复用能力的进步。比gaiix的输出读数的数量更高，可导致RNA-Seq的库多路复用能力更高，导致每个样本的费用较小，动态范围比微阵列分析更好，可靠地检测到低丰度转录本的能力，并发现对整个转录组，小型或无编码RNA RNA RNA发现和基因发现和基因发现和基因发现的新颖转录物。 HISEQ2500花费更少的时间来完成DNA-蛋白调节相互作用，表观遗传调节，整个基因组测序，外显子组测序，与患者DNA转化研究中大型基因组区域的重新测序的广泛基因组，以发现引起突变的人类疾病和转换人类的转化性化合物研究。 HISEQ2500对于将当前的NIH资助项目提升到一个新的水平，以及在俄亥俄州东北部的新努力中至关重要。克利夫兰诊所已经通过在基因组医学研究所内建立LRI基因组核心并在较大的研究核心服务基础设施中支持其运作，以确保其长期的运作和维护。